Eli Lilly and

Eli Lilly and

Yahoo Finance • 4 hours ago

Why A Biotech M&A Wave May Hit This Winter

Biotech stocks have slumped from their August highs. But experts say renewed M&A, likely coming, could catalyze them. Continue Reading... Full story

Yahoo Finance • 5 hours ago

Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer

Prelude Therapeutics, Incorporated Combination cohorts are part of Prelude's Phase 1 trial evaluating PRT13722 in patients with HR+/HER2- breast cancer, on track to initiate enrollment in the fourth quarter of 2026 The collaboration is u... Full story

Yahoo Finance • 17 hours ago

Biogen (BIIB) Stock Is Up, What You Need To Know

Biogen (BIIB) Stock Is Up, What You Need To Know What Happened? Shares of biotech company Biogen (NASDAQ:BIIB) jumped 3.5% in the pre-market session after JPMorgan upgraded the stock to Overweight from Neutral with a $300 price target, r... Full story

Yahoo Finance • 20 hours ago

Sector Update: Healthcare Stocks Rise Late Afternoon

Healthcare stocks rose late Monday afternoon, with the NYSE Healthcare Index and the State Street He PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • yesterday

2 S&P 500 Stocks to Own for Decades and 1 We Find Risky

2 S&P 500 Stocks to Own for Decades and 1 We Find Risky The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn't mean every stock is worth owning. Some companies face significant challenges, whether it's st... Full story

Yahoo Finance • yesterday

Eli Lilly (LLY) Phase 3b Win Connects Psoriasis And Obesity Treatment

Eli Lilly (NYSE: LLY) reported new Phase 3b data on a combined Taltz and Zepbound regimen for adults with plaque psoriasis and obesity. The study linked broader immunometabolic biomarker shifts to the dual therapy, suggesting a biological... Full story

Yahoo Finance • yesterday

Eli Lilly Likely to Raise Revenue Outlook Amid Strong Diabetes, Weight-Loss Drug Sales, RBC Says

Eli Lilly (LLY) is likely to raise its full-year revenue outlook as third-quarter sales momentum in PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • yesterday

JPMorgan gets bullish on Biogen ahead of 2027 catalysts

Investing.com -- JPMorgan lifted its rating for Biogen to Overweight from Neutral on Monday, pointing to a stronger run of clinical catalysts in 2027 and an improved long-term growth outlook. Before you buy NVIDIA: our AI model's stock pi... Full story

Yahoo Finance • 3 days ago

Veeva Systems’ (VEEV) Comeback Gets Jim Cramer Talking

During the October 7 episode of Mad Money, Jim Cramer discussed Veeva Systems Inc. (NYSE:VEEV) as an example of a software business that had recovered from fears about AI disruption, as he said: Take Veeva Systems, the best of its busines... Full story

Yahoo Finance • 4 days ago

3 Biotech Stocks To Watch In October 2026

Rising U.S. interest rate expectations, highlighted by the St. Louis Fed hinting at possible hikes over the next 6 to 9 months, keep pressure on expensive, story driven assets. That focus on higher borrowing costs puts a premium on medical... Full story

Yahoo Finance • 4 days ago

Record Highs Beckon for Big Caps as Small Caps Lag and Deal Flow Builds

Stock Preachers News Commentary NEW YORK, Oct. 9, 2026 /PRNewswire/ -- Large caps closed out the week near record territory, with the S&P 500 and Nasdaq Composite both finishing higher even after a rocky start to the week. Small caps told... Full story

Yahoo Finance • 4 days ago

Eli Lilly (LLY) As Zepbound And Retatrutide Updates Test Whether More Upside Is Priced In

Eli Lilly (LLY) has shifted back into the spotlight after a run of high profile drug updates, with fresh data on Zepbound, Foundayo and the triple agonist retatrutide resetting market attention on its pipeline. After a choppy few months w... Full story

Yahoo Finance • 4 days ago

Combining Eli Lilly's Taltz with Zepbound could enhance psoriasis, metabolic benefits

[Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals.] jetcityimage * An analysis of an ongoing study indicates that there may be synergies in improving both psoriasis and metabolic benefits when Eli Lill... Full story

Yahoo Finance • 4 days ago

Eli Lilly (LLY) Posted 48% Revenue Growth. Why Does the Stock Trade Below Its Average Multiple?

Eli Lilly (NYSE:LLY) reported 48% revenue growth for the second quarter of 2026 a while ago and raised its outlook for the year. Yet the stock trades at 30.94 times forward earnings, as of October 6, well below the 45.59 it has averaged ov... Full story

Yahoo Finance • 4 days ago

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity

Exploratory data presented at Fall Clinical 2026 showed broader biomarker changes with Taltz and Zepbound vs. Taltz alone as early as Week 12 in first-of-its-kind TOGETHER-PsO study INDIANAPOLIS, Oct. 9, 2026 /PRNewswire/ -- Eli Lilly and... Full story

Yahoo Finance • 4 days ago

Eli Lilly-backed TRexBio prices $117M US IPO at $14 per share

[IPO Concept with Stock Market Graphs] AlexSecret * TRex Bio (TRXB [https://seekingalpha.com/symbol/TRXB]) prices IPO at $14 per share, offering 8.33 million shares to the public, as the clinical-stage biotech company focuses on develop... Full story

Yahoo Finance • 5 days ago

Eli Lilly (LLY) Has a Powerful Growth Flywheel Beyond Its GLP-1 Success

Andrew Hill Investment Advisors recently released its third-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund navigated a mixed third-quarter investment environment in which rising oil prices, higher inter... Full story

Yahoo Finance • 5 days ago

How to invest in healthcare stocks without picking the next Eli Lilly

It's always tempting as an investor to try to find the next big winner, and healthcare stocks have been one area where many investors are looking. The explosion in the popularity of GLP-1 medications such as Ozempic and Mounjaro is one su... Full story

Yahoo Finance • 5 days ago

Veeva Summit to Showcase AI Innovations and the Leaders Transforming R&D and Quality

Eli Lilly and Company, Pfizer, Sanofi, UCB, and more share learnings speeding drug development, connecting trials, and modernizing quality and manufacturing PLEASANTON, Calif., Oct. 8, 2026 /PRNewswire/ -- At Veeva R&D and Quality Summit... Full story

Yahoo Finance • 5 days ago

Dow Jones Futures Fall As Oil Prices, Treasury Yields Jump; Samsung, Micron, Taiwan Semi, Sandisk In Focus

Futures fell as oil prices and Treasury yields jumped. Samsung, Taiwan Semi results fall to cheer investors. Continue Reading... Full story